Compare GRRR & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GRRR | TECX |
|---|---|---|
| Founded | 2001 | 2019 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 311.9M | 359.0M |
| IPO Year | N/A | 2018 |
| Metric | GRRR | TECX |
|---|---|---|
| Price | $11.26 | $20.88 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $18.00 | ★ $81.20 |
| AVG Volume (30 Days) | ★ 738.3K | 325.0K |
| Earning Date | 11-17-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $99,747,682.00 | N/A |
| Revenue This Year | $36.15 | N/A |
| Revenue Next Year | $68.68 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 47.86 | N/A |
| 52 Week Low | $10.85 | $13.70 |
| 52 Week High | $44.15 | $61.07 |
| Indicator | GRRR | TECX |
|---|---|---|
| Relative Strength Index (RSI) | 34.59 | 56.27 |
| Support Level | $11.60 | $17.79 |
| Resistance Level | $12.59 | $22.00 |
| Average True Range (ATR) | 0.75 | 1.19 |
| MACD | -0.17 | 0.16 |
| Stochastic Oscillator | 0.98 | 74.35 |
Gorilla Technology Group Inc is engaged in providing information, software, and data processing services. It is a provider of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology (OT) security solutions and services. Its reportable segments are video IoT and security convergence and Other segments.
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.